The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.
about
The Geogenomic Mutational Atlas of Pathogens (GoMAP) web systemTribute to Mark WainbergSubtype-associated differences in HIV-1 reverse transcription affect the viral replication.Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimenIdentification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India.Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsSubunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.Retrovirus reverse transcriptases containing a modified YXDD motif.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.Antiretroviral drug resistance in human immunodeficiency virus type 2.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Mutation rates and intrinsic fidelity of retroviral reverse transcriptases.Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial.
P2860
Q28541636-095D6FEB-ED05-49CD-8267-66135172A490Q33846297-AA372933-75FF-485B-83EC-335932C5BE09Q34243467-835313E0-F853-4D2F-8F49-FCC090724234Q34680647-079612E3-D9D6-484A-9FC1-1EC8959523F2Q34781890-BAC32239-CBF4-4CA3-B0A0-A40620585584Q35579833-FD3F5B05-BCC7-42F3-B065-1991B599D601Q35636029-B600CCE0-63FF-4BB3-B4B5-72FD6126BE2BQ36172087-0535F2A8-A0FD-41E9-AB9B-AF800DE55404Q36186797-BCEBF39E-73A2-4B6C-BAC8-26484DD5D9FEQ36246775-05378A14-CCC6-4215-BE9E-FF6F3D9D6847Q36747913-B8D3C17E-6D3B-4727-84CA-F60E1FA40547Q37496287-AFDBC044-4C7E-46A2-9DDC-ED55DF632B90Q37547275-C26327CA-6A2A-4CA0-BD32-F5B776534499Q37945186-D56236D2-436F-4F8B-9EFB-0D813862A0F2Q40820470-A0CECF63-5828-424B-8462-34B6EB8F92EB
P2860
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
The M184V substitution in huma ...... ype B and C clinical isolates.
@en
The M184V substitution in huma ...... ype B and C clinical isolates.
@nl
type
label
The M184V substitution in huma ...... ype B and C clinical isolates.
@en
The M184V substitution in huma ...... ype B and C clinical isolates.
@nl
prefLabel
The M184V substitution in huma ...... ype B and C clinical isolates.
@en
The M184V substitution in huma ...... ype B and C clinical isolates.
@nl
P2093
P2860
P1476
The M184V substitution in huma ...... ype B and C clinical isolates.
@en
P2093
Bluma Brenner
Daniela Moisi
Karidia Diallo
Mark A Wainberg
Matthias Götte
Maureen Oliveira
Mervi Detorio
P2860
P304
P356
10.1128/AAC.47.7.2376-2379.2003
P407
P577
2003-07-01T00:00:00Z